1,721,239 research outputs found
MSJ892555_supplemental_material – Supplemental material for Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment
Supplemental material, MSJ892555_supplemental_material for Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment by Jeffrey A Cohen, Maria Trojano, Ellen M Mowry, Bernard MJ Uitdehaag, Stephen C Reingold and Ruth Ann Marrie in Multiple Sclerosis Journal</p
sj-docx-1-dhj-10.1177_20552076231173531 - Supplemental material for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
Supplemental material, sj-docx-1-dhj-10.1177_20552076231173531 for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis by Gavin Giovannoni, Enrique Alvarez, Ellen Tutton, Olaf Hoffmann, Yan Xu, Patrick Vermersch, Celia Oreja-Guevara, Maria Trojano, Ralf Gold, René Robles-Cedeño, Mudeer Khwaja, Bianca Stadler, Jo Vandercappellen and Tjalf Ziemssen in DIGITAL HEALTH</p
sj-docx-1-tan-10.1177_17562864211042458 – Supplemental material for No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
Supplemental material, sj-docx-1-tan-10.1177_17562864211042458 for No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP) by Helmut Butzkueven, Ludwig Kappos, Tim Spelman, Maria Trojano, Heinz Wiendl, Ray Su, Shirley Liao, Robert Hyde, Stephanie Licata, Pei-Ran Ho and Nolan Campbell in Therapeutic Advances in Neurological Disorders</p
sj-png-3-dhj-10.1177_20552076231173531 - Supplemental material for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
Supplemental material, sj-png-3-dhj-10.1177_20552076231173531 for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis by Gavin Giovannoni, Enrique Alvarez, Ellen Tutton, Olaf Hoffmann, Yan Xu, Patrick Vermersch, Celia Oreja-Guevara, Maria Trojano, Ralf Gold, René Robles-Cedeño, Mudeer Khwaja, Bianca Stadler, Jo Vandercappellen and Tjalf Ziemssen in DIGITAL HEALTH</p
sj-docx-6-dhj-10.1177_20552076231173531 - Supplemental material for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
Supplemental material, sj-docx-6-dhj-10.1177_20552076231173531 for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis by Gavin Giovannoni, Enrique Alvarez, Ellen Tutton, Olaf Hoffmann, Yan Xu, Patrick Vermersch, Celia Oreja-Guevara, Maria Trojano, Ralf Gold, René Robles-Cedeño, Mudeer Khwaja, Bianca Stadler, Jo Vandercappellen and Tjalf Ziemssen in DIGITAL HEALTH</p
sj-png-4-dhj-10.1177_20552076231173531 - Supplemental material for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
Supplemental material, sj-png-4-dhj-10.1177_20552076231173531 for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis by Gavin Giovannoni, Enrique Alvarez, Ellen Tutton, Olaf Hoffmann, Yan Xu, Patrick Vermersch, Celia Oreja-Guevara, Maria Trojano, Ralf Gold, René Robles-Cedeño, Mudeer Khwaja, Bianca Stadler, Jo Vandercappellen and Tjalf Ziemssen in DIGITAL HEALTH</p
sj-docx-2-dhj-10.1177_20552076231173531 - Supplemental material for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
Supplemental material, sj-docx-2-dhj-10.1177_20552076231173531 for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis by Gavin Giovannoni, Enrique Alvarez, Ellen Tutton, Olaf Hoffmann, Yan Xu, Patrick Vermersch, Celia Oreja-Guevara, Maria Trojano, Ralf Gold, René Robles-Cedeño, Mudeer Khwaja, Bianca Stadler, Jo Vandercappellen and Tjalf Ziemssen in DIGITAL HEALTH</p
sj-png-5-dhj-10.1177_20552076231173531 - Supplemental material for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
Supplemental material, sj-png-5-dhj-10.1177_20552076231173531 for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis by Gavin Giovannoni, Enrique Alvarez, Ellen Tutton, Olaf Hoffmann, Yan Xu, Patrick Vermersch, Celia Oreja-Guevara, Maria Trojano, Ralf Gold, René Robles-Cedeño, Mudeer Khwaja, Bianca Stadler, Jo Vandercappellen and Tjalf Ziemssen in DIGITAL HEALTH</p
Going Beyond Counting First Authors in Author Co-citation Analysis
The present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
